baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GILEAD SCIENCES/ US3755581036 /

05/04/2024 18:23:03	Chg. -4.45	Volume	Bid03:00:57	Ask03:00:57	Market Capitalization	Dividend Y.	P/E Ratio
64.51EUR	-6.45%	5 Turnover: 322.55	-Bid Size: -	-Ask Size: -	75.36 bill.EUR	-	-

GlobeNewswire 22/05 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 14/05 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GlobeNewswire 09/05 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...

GlobeNewswire 09/05 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 08/05 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire 08/05 Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 19/04 ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...

GlobeNewswire 10/04 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...

GlobeNewswire 03/04 Opthea Appoints Sujal Shah to the Board of Directors

GlobeNewswire 02/04 Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

GlobeNewswire 02/04 Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

GlobeNewswire 01/04 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...

GlobeNewswire 28/03 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...

GlobeNewswire 28/03 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

GlobeNewswire 28/03 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire 22/03 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...

GlobeNewswire 18/03 CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards

GlobeNewswire 11/03 Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...

GlobeNewswire 29/02 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...

GlobeNewswire 29/02 Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...

GlobeNewswire 28/02 CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...

GlobeNewswire 27/02 MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

GlobeNewswire 24/02 SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE

GlobeNewswire 22/02 Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoi...

GILEAD SCIENCES/ US3755581036 /

If you wish to receive reply to your feedback, please provide your email address.